Behavioral: Agitated Patient – Adolescent

Applies to adolescent patients only

Criteria

  • This protocol is intended to be utilized to help outline the approach to an individual in the transitional stage of physical and psychological development between puberty and adulthood in instances in which the adult or pediatric protocol may not provide sufficient guidance
  • This protocol is intended to be used to assist in safe provision of care with agitated adolescent patients requiring medical evaluation, treatment, and transportation
  • This may include any patient who demonstrates potentially violent behavior, regardless of underlying etiology
  • This protocol includes consideration for patients who are extremely combative and are at immediate risk of causing physical harm to emergency responders, the public, and/or themselves
  • Pharmacologic management of behavioral emergencies is only to be utilized for situations in which environmental modification and verbal de-escalation (utilizing interpersonal communication skills) is not successful or not possible
  • See De-escalation Techniques and Altered Mental Status

All levels

  • Airway management, vital signs, and appropriate oxygen therapy, if tolerated
  • Verbal de-escalation (utilizing interpersonal communication skills)
  • If verbal de-escalation is not successful or not possible, apply soft restraints, such as towels, triangular bandages, or commercial medical restraints, only if necessary to protect the patient and others from harm

EMT and up

  • Check blood glucose level‡, as soon as you are able to safely do so. If low, see Hypoglycemia - Adult.

CC and up

  • Midazolam (Versed) up to 5 mg IM or IV; may repeat up to 10 mg

Paramedic

  • Olanzapine 10 mg IMⓟ‡ once, or 5mg SLⓟ‡ once – use caution if midazolam given or anticipated
  • For patients who are extremely combative and are at immediate risk of causing physical harm to emergency responders, the public, and/or themselves who present with a clinical triad of psychomotor agitation, physiologic excitation, and failure to respond to verbal and environmental de-escalation in the setting of destructive, erratic, bizarre, or violent behavior. Common features include:
  • Unusual strength
  • Lack of tiring
  • Unnatural pain tolerance
  • Tachypnea
  • Diaphoresis
  • Psychomotor agitation
  • Tactile hyperthermia
  • Altered mental status
  • Ketamineⓟ‡ 2 mg/kg up to 250 mg IM OR Midazolam (Versed) 0.1 mg/kg up to 5 mg IM; may repeat Midazolam (Versed) up to 10 mg
  • May administer Ketamineⓟ‡ 2 mg/kg up to 250 mg IM after 5 minutes (as a single repeat dose or as a single dose after Midazolam [Versed]), should the patient remain uncontrolled
  • If the agitated patient goes into cardiac arrest, refer to the appropriate protocol and Sodium Bicarbonate 50 mEq IV

Medical control

  • Midazolam (Versed) IV, IM
  • Ketamineⓟ‡ 0.5-2 mg/kg IV or IM
  • Consider initial dose of Ketamine 250 mg IM for the appropriate patient
  • Use caution ordering Ketamine after Midazolam (Versed) because apnea may occur

Key points

  • Patient must NOT be transported in a face-down position
  • Assess the scene for safety and, if it is not, retreat to a safe location and obtain police assistance
  • Consider medical causes of abnormal behavior such as hypoxia, hypoperfusion, hypoglycemia, head injury, intoxication, other drug ingestion, and trauma
  • Consider the possibility of a behavioral/developmental disorder such as autism spectrum disorder or mental health problems
  • Utilize waveform capnography as soon as practicable following administrations of any medications in this protocol
  • A team approach should be attempted at all times for the safety of the patient and the providers
  • If the patient is in police custody and/or has handcuffs on, a police officer should accompany the patient in the ambulance to the hospital. EMS must have the ability to immediately remove any mechanical restraints that hinder patient care at all times.
  • All uses of this protocol may require Agency Medical Director review or regional QA, depending on regional procedure
Collaborative 26.2 · pp. 44–45BLS version